PharmaTelevision - sanofi-aventis’ New Direction

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: sanofi-aventis’ New Direction

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Since Chris Viehbacher joined sanofi-aventis as CEO his aim has been to get the company recognised as a global healthcare company and not solely as a producer of vaccines. Jean-Claude Muller, Senior VP, Strategic and Prospective Initiatives, is at the forefront of this effort actively seeking new areas and markets that they can expand into. Here he discusses the recent acquisition of BiPar Sciences and the new deal with Oxford BioMedica as examples of how sanofi-aventis hopes to achieve its goals.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Role of Jean Claude Muller within sanofi-aventis.

Fintan Walton:

Hello and welcome. We are here at Bio 2009 at the annual convention here in Atlanta. We are here to record a series of programs with leading pharmaceutical and bio technology companies to talk about both their vision and what they are doing to build their organizations in tough economic times.

Fintan walton:

Hello and welcome to pharmaventures business review here at Bio in Atlanta. On this show I have Jean Claude Muller who is senior vice president of Prospective and Strategic Initiatives at Sanofi-aventis. Welcome to the show.

Jean Claude Muller:

Good morning Fintan.

Fintan walton:

Good morning. Jean Claude Mullercan you describe what your role is specifically within sanofi-aventis organization?

Jean Claude Muller:

I am currently in charge of a department called Prospective and strategic initiatives at the corporate level based in Paris and the main feature there is let's say prepare the future and then look how to best move into let's say new areas and currently I am mainly in charge of preparing R&D 2015 to see which could be let's say new streams, new activities, new areas of interest. chris viehbacher when he arrived in December first said clearly that we want to move into new areas to become a global healthcare company and we are known to be a pharma in the vaccine business but we are currently already be able let's say very active in some areas and what I am currently which could be areas for growths and which could be areas of let's say major impact for the company and for the patients.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jean Claude Muller

Senior VP Prospective and strategic initiatives

Jean Claude Muller,Senior VP Prospective&Strategic Initiatives sanofi-aventis Jean Claude Muller Started his career in 1974 as an organic chemist at Roche at Basle (Switzerland). He moved to Nutley (USA) in 1979. In 1983, he joined Synthelabo, Paris (France) where he leaded the cardiovascular research organization for several years prior to becoming in 1994 a corporate manager in charge of external projects and research alliances at Synthelabo was a deal architect in the genomic alliances with Human Genome Sciences, Inc. (USA) and Genset (France) and the acquisition of the Strasbourg Research facility from Hoechst Marion Roussel. In 1992, he was the Strategic Corporate Manager Responsible for the Assessment of External Opportunities, the Identification and Implementation of R&D Alliances and the Competitive Intelligence Surveys. In 2003, he became Vice-President Administration & Resources. He was in charge of the integration between sanofi and aventis, of managing the resources and budget of sanofi-aventis R&D and in charge of Instrumental in the alliance building with Regeneron. Since November 2008, he is a Current Senior Vice President Prospective & Strategic Initiatives he is in charge of constructing R&D 2015.

Sanofi-aventis

Sanofi-aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's third-largest by prescription sales. sanofi-aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. sanofi-aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur. The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).